Evidence map›Paper›PMID 41135058›Full record

ArticleBlood advances2026

Low bone mineral density and pain impact in adults with sickle cell disease.

Oyebimpe O Adesina, Jenna Voutsinas, Qian V Wu, Leyla Y Teos, Mehrad Rokni, Hande Nalbant, Lorenzo Nardo, Ted Wun, Babette Zemel

Registry-linked trialAbstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05283148 (Association Between Low Bone Density, Vertebral Fractures, and Pain in Sickle Cell Disease), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05283148 naactive not recruitingnot on this map

Association Between Low Bone Density, Vertebral Fractures, and Pain in Sickle Cell Disease

TypeinterventionalSponsorUniversity of California, DavisRan2022 to 2026Enrolled53ConditionsSickle Cell Disease, Sickle Cell Anemia, Low Bone Density, OsteoporosisArmsDual-energy X-ray absorptiometry, Vertebral fracture analysis, Adult Sickle Cell Quality of Life Measurement System pain impact questionnaire
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oyebimpe O AdesinaDivision of Hematology and Oncology, Department of Medicine, University of California Davis, Sacramento, CA.ORCID 0000-0002-3082-9114
Jenna VoutsinasDepartment of Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-7474-4892
Qian V WuDepartment of Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA.ORCID 0000-0002-2292-4816
Leyla Y TeosDivision of Hematology and Oncology, Department of Medicine, University of California Davis, Sacramento, CA.
Mehrad RokniDepartment of Radiology, University of California Davis, Sacramento, CA.ORCID 0009-0008-4965-4407
Hande NalbantDepartment of Radiology, University of California Davis, Sacramento, CA.ORCID 0000-0002-8600-6707
Lorenzo NardoDepartment of Radiology, University of California Davis, Sacramento, CA.ORCID 0000-0002-0266-2708
Ted WunDivision of Hematology and Oncology, Department of Medicine, University of California Davis, Sacramento, CA.ORCID 0000-0001-6383-7172
Babette ZemelDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0002-6164-7348

Funding

A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell diseaseK23HL148310 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ADESINA, OYEBIMPE OLUYEMISI · 2021 to 2025
$925k
NHLBI NIH HHS K23 HL148310
6 · The paper itself

Abstract

abstractLow bone mineral density (BMD) is a prevalent skeletal finding in sickle cell disease (SCD), but its clinical consequences are poorly understood. We hypothesized that low BMD, independent of osteonecrosis (ON), would associate with pain in adults with SCD. In the SCD Bone Pain study, 53 ambulatory adults (64% females; mean age, 38 ± 11 years; 66% hemoglobin [Hb] SS/Sβ0 thalassemia) underwent dual-energy X-ray absorptiometry scans of their lumbar spine, hip, forearm, and whole body. They also completed the Adult Sickle Cell Quality of Life Measurement Information System pain impact questionnaire. Twenty-three participants (43%) had low BMD, defined as lumbar spine, total hip, or femoral neck BMD z scores of -2 or less. In multivariate linear regression, lumbar spine BMD z scores significantly changed by +0.31, -0.29, -0.14, and -1.3 for every unit increase in Hb, indirect bilirubin, and white blood cell count, and with crizanlizumab use, respectively. Pain impact T-scores significantly decreased (worsened) by 6.0 and 6.5 with reduced estimated glomerular filtration rate and chronic opioid therapy but increased (improved) by 3.8 for every unit increase in serum phosphate. The median [interquartile range] pain impact T-scores were significantly lower in participants with low BMD and ON (38.3 [37.4, 40.1]) than those with either low BMD (49.5 [43.6, 54.4]; P = 3 × 10-5) or ON (52.7 [45.3, 57]; P = 2 × 10-4) alone. Whether sickle cell-related low BMD results from impaired bone formation and/or accelerated bone loss remains unclear. Understanding how low bone density, with or without ON, mediates SCD pain warrants further investigation. This trial was registered at www.clinicaltrials.gov as #NCT05283148.

Indexed as

Anemia, Sickle CellBone DensityPainAbsorptiometry, PhotonAdultFemaleHumansMaleMiddle AgedQuality of Life

Identifiers

PMID41135058
PMCPMC12874296

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.